Redx Pharma PLC (AIM: REDX) announced that its primary asset, RXC007, is successfully moving through phase IIa testing, with anticipated results from the idiopathic pulmonary fibrosis research due in the
Why UK small-cap biotech shares are going extinct, AVCT, RENE, POLX, HVO & HEMO
When a UK biotech firm starts to show promise, they set sail across the Atlantic. Investors can’t blame them.
The Essential Investing Strategy Review For 2023, HARL, PREM, AVCT, & BOIL
Buying lottery tickets on the FTSE AIM can be very rewarding, but only for investors who have already properly diversified.
Diversification: the essential investing strategy for 2023
Buying lottery tickets on the FTSE AIM can be very rewarding, but only for investors who have already properly diversified.
Redx Pharma plc (AIM:REDX) Collaboration with the Garvan Institute
Redx Announces Collaboration with the Garvan Institute of Medical Research
Women are pushing forward groundbreaking Alzheimer’s treatment ideas that go beyond the headlines
The medical community is now closer than ever to finding treatments for Alzheimer’s disease.
The highs and lows of drug launches
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,
Redx Pharma plc (REDX.L) Out licensing agreement with AstraZeneca
Lisa Anson, Chief Executive Officer of Redx Pharma, commented : “We are excited by the potential of porcupine inhibition as a novel approach to tackling fibrotic-associated diseases where there is
OKYO Pharma LTD (OKYO.L) Issue of convertible loan notes to raise £3,500,000
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS
Is OKYO Pharma (OKYO.L) the next Tiziana Life Sciences (TILS.L)
Pharma stocks have strengthened in 2020
Open Orphan PLC (LON:ORPH) New hVIVO contract signed with a European Biotech Company
Initial study for the provision of a RSV human challenge study